SOUTH SAN FRANCISCO (dpa-AFX) - Roche (RO.SW, ROG.SW) announced the FDA has approved Enspryng for the treatment of adults with thyroid eye disease. Enspryng can be administered by a person living with TED or a caregiver following training from a healthcare provider. The FDA approval was based on Phase III SatraGO-1 and -2 studies.
The latest approval, following a priority review designation, marks the second indication for Enspryng, following an approval in neuromyelitis optica spectrum disorder in 2020. This follows a recent acceptance by the FDA for priority review in myelin oligodendrocyte glycoprotein antibody-associated disease.
At previous close on SIX Exchange, Roche shares were trading at 379.70 Swiss francs.
For More Such Health News, visit rttnews.com.
Copyright(c) 2026 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
© 2026 AFX News
